Business
New Mymetics data to be presented by LMIV at American Society of Tropical Medicine and Hygiene
New Mymetics data to be presented by LMIV at American Society of Tropical Medicine and Hygiene.
About this update from Mymetics Corp.
[{"type":"text","content":"\n\n\n\nNew Mymetics data to be presented by LMIV at American Society of Tropical Medicine and Hygiene\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nNew Mymetics data to be presented by LMIV at American Society of Tropical Medicine and Hygiene\n- Poster presentation showing pre-clinical in vivo results investigating antibody titer strength, duration and functionality of malaria transmission blocking Pfs230 virosome-based vaccine compared to a benchmark formulation\n- Poster presentation at ASTMH - New Orleans, Louisiana, USA, Tuesday October 30th, 2018\nPR Newswire\nEPALINGES, Switzerland, Oct. 30, 2018\n\n\n\nEPALINGES, Switzerland, Oct. 30, 2018 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases announces that new data will be presented at the 67th American Society of Tropical Medicine and Hygiene (ASTMH), held from October 28 – November 1, 2018 at in New Orleans, Louisiana.\nDr. David L. Narum of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will discuss the results from an ongoing study in CD-1 mice investigating antibody titer strength, duration and functionality following Pfs230D1M antigen delivered in Mymetics' influenza virosome platform containing a membrane anchored TLR4 and/or TLR7/8 agonist. Included as a comparator is a point of injection formulation of Pfs230D1M-EPA with a TLR4 agonist and QS-21 in a liposomal formulation, similar to the clinical benchmark.\nThe poster with the title \"Evaluation of the malaria transmission blocking vaccine antigen Pfs230D1M in an influenza virosome platform containing TLR agonists\", will be presented on October 30th from noon to 1:45pm.\nThe poster highlights that virosomes containing the Pfs230D1M antigen and TLR7/8 agonist produced durable Pfs230D1M antibody titers over a period of 126 Days in CD-1 mice. \nThe titers and functional activity of s...